Hit enter to search or ESC to close
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
AI-POWR™
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
Robert Foster Discusses Drug Development on Humble & Fred Morning Radio Podcast
By
Hepion
August 27, 2020
December 2nd, 2020
Media Placements
No Comments
https://hepionpharma.com/wp-content/uploads/2020/08/Humble-and-Fred-200827-dr-robert-foster-clip.mp3
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
March 23, 2021
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
March 22, 2021
Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
March 11, 2021
Share
Tweet
Share
Pin
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
AI-POWR™
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
